|
|
|
Agendia was founded in 2003 by Netherlands Cancer Institute (NKI). The company is a world leader in gene expression analysis-based diagnostics and has developed a series of validated, state of the art tests using tumor gene expression profiling to determine tumor specific properties. These in vitro tests offer physicians and pharmaceutical companies improve the accuracy of metastasis risk prediction, disease origin, targeted drug development or pre-selection of patients eligible for clinical trials. Agendia was the first company to commercialise a prognostic test, MammaPrint, which predicts the risk of breast cancer recurrence. MammaPrint was cleared by the US Food and Drugs Administration (FDA) in February 2007.
More info: http://www.agendia.com/
|
|
